No abstract

OnabotulinumtoxinA at doses of 100 U or greater demonstrated durable efficacy in the management of idiopathic overactive bladder and urinary urgency incontinence. A dose of 100 U may be the dose that appropriately balances the symptom benefits with the post-void residual urine volume related safety profile.

Key Points• AML1/ETO triggers the heterochromatic silencing of miR193a and PTEN by binding at AML1-binding sites and recruiting epigenetic enzymes.• A feedback circuitry involving miR-193a and AML1/ETO/ DNMTs/HDACs, cooperating with the PTEN/PI3K pathway and contributing to leukemogenesis.

Improvements in urodynamic parameters and clinical outcomes generally trended together following onabotulinumtoxinA treatment. This therapy improved key urodynamic parameters in patients with idiopathic OAB and UUI, with no differences in outcomes between those with and those without baseline DO. Therefore, successful idiopathic OAB treatment with onabotulinumtoxinA does not appear to be related to pretreatment finding of DO.